Comparative Therapeutic Potential of ALX-0171 and Palivizumab against Respiratory Syncytial Virus Clinical Isolate Infection of Well-Differentiated Primary Pediatric Bronchial Epithelial Cell Cultures-Reference-Cited by-同舟云学术

Comparative Therapeutic Potential of ALX-0171 and Palivizumab against Respiratory Syncytial Virus Clinical Isolate Infection of Well-Differentiated Primary Pediatric Bronchial Epithelial Cell Cultures

Published:2020-01-27 Issue:2 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Broadbent Lindsay¹,Parke Hong Guo¹,Ferguson Lyndsey J.¹,Millar Andrena¹,Shields Michael D.¹²,Detalle Laurent³,Power Ultan F.¹

Affiliation:

1. Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom

2. Royal Belfast Hospital for Sick Children, Belfast Health & Social Care Trust, Belfast, United Kingdom

3. Ablynx NV, Ghent, Belgium

Abstract

Respiratory syncytial virus (RSV) causes severe lower respiratory tract infections in young infants. There are no RSV-specific treatments available. Ablynx has been developing an anti-RSV F-specific nanobody, ALX-0171. To characterize the therapeutic potential of ALX-0171, we exploited our well-differentiated primary pediatric bronchial epithelial cell (WD-PBEC)/RSV infection model, which replicates several hallmarks of RSV disease in vivo .

Funder

Ablynx

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02034-19

Reference44 articles.

1. Taxonomy of the order Mononegavirales: update 2016

2. Respiratory syncytial virus infections in children

3. The Burden of Respiratory Syncytial Virus Infection in Young Children